6-(苄氧基)-二氢吲哚 | 19727-90-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 6-(苄氧基)-二氢吲哚
• 英文名称: 6-(benzyloxy)-indoline
• 英文别名: 6-(Benzyloxy)indoline；6-phenylmethoxy-2,3-dihydro-1H-indole
• CAS: 19727-90-3
• 化学式: C₁₅H₁₅NO
• 分子量: 225.29
• InChiKey: FXOYDLLFRGNRMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-(苄氧基)-二氢吲哚 、 苯甲酰基异硫氰酸酯 以 丙酮 为溶剂， 反应 8.0h， 生成 N-(6-benzyloxy-2,3-dihydro-indole-1-carbothioyl)-benzamide
  参考文献：
  名称：

  Design and synthesis of indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives as novel HCV inhibitors

  摘要：

  An efficient synthetic methodology to provide indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives is described. These conformationally restricted heterobicyclic scaffolds were evaluated as a novel class of HCV inhibitors. Introduction of an acyl group at the NH2 of the thiourea moiety has been found to enhance inhibitory activity. The chain length and the position of the alkyl group on the indoline aromatic ring markedly influenced anti-HCV activity. The indoline scaffold was more potent than the corresponding indole and tetrahydroquinoline scaffolds and analogue 31 displayed excellent activity (EC50 = 510 nM) against HCV without significant cytotoxicity (CC50 > 50 mu M). (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.009
• 作为产物：
  描述：

  6-苄氧基吲哚 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 反应 8.0h， 生成 6-(苄氧基)-二氢吲哚
  参考文献：
  名称：

  Design and synthesis of indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives as novel HCV inhibitors

  摘要：

  An efficient synthetic methodology to provide indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives is described. These conformationally restricted heterobicyclic scaffolds were evaluated as a novel class of HCV inhibitors. Introduction of an acyl group at the NH2 of the thiourea moiety has been found to enhance inhibitory activity. The chain length and the position of the alkyl group on the indoline aromatic ring markedly influenced anti-HCV activity. The indoline scaffold was more potent than the corresponding indole and tetrahydroquinoline scaffolds and analogue 31 displayed excellent activity (EC50 = 510 nM) against HCV without significant cytotoxicity (CC50 > 50 mu M). (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.009

文献信息

• CYANOQUINOLINE DERIVATIVES
  申请人：Zhang Hesheng

  公开号：US20130225579A1

  公开（公告）日：2013-08-29

  Disclosed is a compound of formula I, a stereoisomer thereof, a cis-trans-isomer thereof, a tautomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof, wherein R 1 , R 2 , R 3 and R 4 are each as defined in the present application.

  公开了一种公式I的化合物，其立体异构体，其顺反异构体，其互变异构体，或它们的混合物，或其药物可接受的盐，其溶剂化物或其前药，其中R1，R2，R3和R4各自如在本申请中定义。
• Highly chemoselective reduction using a Rh/C–Fe(OAc)2 system: practical synthesis of functionalized indoles
  作者：Atsushi Akao、Kimihiko Sato、Nobuaki Nonoyama、Toshiaki Mase、Nobuyoshi Yasuda

  DOI：10.1016/j.tetlet.2005.11.145

  日期：2006.2

  Here, we report a highly effective and chemoselective method of preparing substituted indoles from (E)-2-nitropyrrolidinostyrenes via hydrogenation in the presence of a rhodium catalyst doped by additives such as Ni(NO3)2·6H2O, Fe(OAc)2 or Co(acac)3. These hydrogenation conditions may also be applied to other substrates. Aromatic nitro compounds and olefins can be selectively reduced in the presence

  这里，我们报告从（制备取代的吲哚的一个非常有效的和化学选择性方法ë）-2- nitropyrrolidinostyrenes通过氢化在铑催化剂掺杂的存在下，通过添加剂如Ni（NO 3）2 ·6H 2 O，Fe（上OAC ）2或Co（acac）3。这些氢化条件也可以应用于其他基材。在芳族苄基醚，芳族卤化物和芳族醛的存在下，可以选择性地还原芳族硝基化合物和烯烃。
• Phenylaminopropanol derivatives and methods of their use
  申请人：Mahaney Erin Paige

  公开号：US20070072897A1

  公开（公告）日：2007-03-29

  The present invention is directed to phenylaminopropanol derivatives of formulae I, II, and III: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof.

  本发明涉及具有以下结构的苯基氨基丙醇衍生物：或其药学上可接受的盐、含有这些衍生物的组合物，以及它们用于预防和治疗由单胺再摄取改善的病况的方法，包括但不限于血管运动症状（VMS）、性功能障碍、胃肠和泌尿系统疾病、慢性疲劳综合征、纤维肌痛综合征、神经系统疾病和其组合，特别是从以下组中选出的主要抑郁症、血管运动症状、压力性和切欲性尿失禁、纤维肌痛、疼痛、糖尿病神经病变、精神分裂症和其组合。
• 4-heterocyclyl-substituted quinazoline derivatives, processes for their
  申请人：Pfizer Inc.

  公开号：US05736534A1

  公开（公告）日：1998-04-07

  This invention relates to certain 4-aminoquinazolines and the pharmaceutically acceptable salts and stereoisomers thereof, the formula whereof are described herein. The compounds are useful for the treatment of hyperproliferative diseases, particularly as anti-cancer agents.

  本发明涉及某些4-氨基喹唑啉及其药学上可接受的盐和立体异构体，其化学式如下所述。这些化合物对于治疗增殖过度性疾病，特别是作为抗癌药物，具有用途。
• PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150353505A1

  公开（公告）日：2015-12-10

  The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了公式（I）的化合物或其立体异构体，互变异构体或药学上可接受的盐，其中所有变量如此定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗心血管，平滑肌，肿瘤，神经病理，自身免疫，纤维化和/或炎症性疾病的方法。